Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance 

Published byChrister Lindberg Modified over 6 years ago

Similar presentations

Presentation on theme: "Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance "— Presentation transcript:

1 Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance  Paul D. Thompson, MD, Diane E. MacDougall, MS, Roger S. Newton, PhD, Janice R. Margulies, MS, Jeffrey C. Hanselman, MS, David G. Orloff, MD, James M. McKenney, PharmD, Christie M. Ballantyne, MD  Journal of Clinical Lipidology  Volume 10, Issue 3, Pages (May 2016) DOI: /j.jacl Copyright © 2016 National Lipid Association Terms and Conditions

2 Figure 1 Disposition of patients. *One patient who was statin tolerant was randomized but discontinued before receiving study drug. EZE, ezetimibe; mITT, modified intent-to-treat; Pop., population. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

3 Figure 2 Percent changes from baseline in LDL-C, stratified by statin tolerance. Week 12 or last observation carried forward is the end-of-study endpoint and differs slightly from week 12 value; P values vs EZE monotherapy were determined by an analysis of covariance model with terms for treatment and statin intolerance and baseline value as a covariate. *P ≤ .05 vs EZE; †P ≤ .01 vs EZE; ‡P < .0001 vs EZE. EZE, ezetimibe; LS, least square. Error bars represent standard error. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

4 Figure 3 Percent changes from baseline in LDL-C by treatment group and time. P values vs EZE at week 12 endpoint are shown. Week 12 or last observation carried forward is the end-of-study endpoint and differs slightly from week 12 value; P values vs EZE monotherapy were determined by an analysis of covariance model with terms for treatment and statin intolerance and baseline value as a covariate. EZE, ezetimibe; LS, least square. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

Download ppt "Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance "

Similar presentations

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double- Blind Study in Men With Diabetes Mellitus  Irwin Goldstein, MD,

Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double- Blind Study in Men With Diabetes Mellitus  Irwin Goldstein, MD,
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Cognitive Safety Task Force: 2014 update
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
A review of PCSK9 inhibition and its effects beyond LDL receptors

A review of PCSK9 inhibition and its effects beyond LDL receptors
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Volume 146, Issue 6, Pages (December 2014)

Volume 146, Issue 6, Pages (December 2014)
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Similar presentations

Ads by Google